Developing biomarkers in mood disorders research through the use of rapid-acting antidepressants

Depression and Anxiety

Volumn 31, Issue 4, 2014, Pages 297-307

  Niciu, Mark J ^a   Mathews, Daniel C ^b   Nugent, Allison C ^a   Ionescu, Dawn F ^a   Furey, Maura L ^a   Richards, Erica M ^a   Machado Vieira, Rodrigo ^a   Zarate, Carlos A ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b LUNDBECK RESEARCH USA   (United States)

Author keywords

biomarker; bipolar depression; bipolar disorder; depression; drug development; major depressive disorder; mediator; moderator; neuroimaging; predictor

Indexed keywords

ANTIDEPRESSANT AGENT; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; CYANOCOBALAMIN; KETAMINE; MICRORNA; MUSCARINIC RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SCOPOLAMINE; ANALGESIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; SCOPOLAMINE BROMIDE;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; CONSTRUCT VALIDITY; ELECTROENCEPHALOGRAPHY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; LOW DRUG DOSE; MAGNETOENCEPHALOGRAPHY; MAJOR DEPRESSION; MOLECULAR BIOLOGY; MOOD DISORDER; NEUROIMAGING; NONHUMAN; PATHOPHYSIOLOGY; POLYSOMNOGRAPHY; PREDICTION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYMPTOMATOLOGY; SYSTEMS BIOLOGY; TREATMENT RESPONSE; VALIDATION STUDY; GENOMICS; METABOLOMICS; METHODOLOGY; MOOD DISORDERS; MULTIMODAL IMAGING; PROCEDURES;

ANALGESICS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL MARKERS; CHOLINERGIC ANTAGONISTS; GENOMICS; HUMANS; KETAMINE; METABOLOMICS; MOOD DISORDERS; MULTIMODAL IMAGING; NEUROIMAGING; RESEARCH DESIGN; SCOPOLAMINE HYDROBROMIDE;

EID: 84898826938     PISSN: 10914269     EISSN: 15206394     Source Type: Journal    
DOI: 10.1002/da.22224     Document Type: Conference Paper

References (58)

1. Mullard A,. 2012 FDA drug approvals. Nat Rev Drug Discov 2013; 12 (2): 87-90.
2. Amur S, Frueh FW, Lesko LJ, et al. Integration and use of biomarkers in drug development, regulation and clinical practice: a US regulatory perspective. Biomark Med 2008; 2 (3): 305-311.
3. Wittchen HU, Jacobi F, Rehm J, et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011; 21 (9): 655-679.
4. Miller G,. Is pharma running out of brainy ideas? Science 2010; 329 (5991): 502-504.
5. Biomarkers Definition Working group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69 (3): 89-95.
6. Nugent AC, Carlson PJ, Bain EE, et al. Mood stabilizer treatment increases serotonin type 1A receptor binding in bipolar depression. J Psychopharmacol 2013; 27 (10): 894-902.
7. Vasan RS,. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113 (19): 2335-2362.
8. Pasco JA, Jacka FN, Williams LJ, et al. Clinical implications of the cytokine hypothesis of depression: the association between use of statins and aspirin and the risk of major depression. Psychother Psychosom 2010; 79 (5): 323-325.
9. Staner L,. Surrogate outcomes in neurology, psychiatry, and psychopharmacology. Dialogues Clin Neurosci 2006; 8 (3): 345-352.
10. Papakostas GI,. Surrogate markers of treatment outcome in major depressive disorder. Int J Neuropsychopharmacol 2012; 15 (6): 841-854.
11. Phillips ML, Vieta E,. Identifying functional neuroimaging biomarkers of bipolar disorder: toward DSM-V. Schizophr Bull 2007; 33 (4): 893-904.
12. Schwarz E, Bahn S,. The utility of biomarker discovery approaches for the detection of disease mechanisms in psychiatric disorders. Br J Pharmacol 2008; 153 (Suppl 1): S133-S136.
13. Karsdal MA, Henriksen K, Leeming DJ, et al. Biochemical markers and the FDA Critical Path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers 2009; 14 (3): 181-202.
14. Lee JW, Devanarayan V, Barrett YC, et al. Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 2006; 23 (2): 312-328.
15. Institute of Medicine of the National Academies. In:, Micheel CM, Ball JR, editors. Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease. Washington D.C.: The National Academies Press; 2010.
16. Wagner JA,. Strategic approach to fit-for-purpose biomarkers in drug development. Annu Rev Pharmacol Toxicol 2008; 48: 631-651.
17. Goodsaid FM, Mendrick DL,. Translational medicine and the value of biomarker qualification. Sci Transl Med 2010; 2 (47): 47ps44.
18. Hayes RL, Robinson G, Muller U, et al. Translation of neurological biomarkers to clinically relevant platforms. Methods Mol Biol 2009; 566: 303-313.
19. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167 (7): 748-751.
20. Klunk WE,. Amyloid imaging as a biomarker for cerebral beta-amyloidosis and risk prediction for Alzheimer dementia. Neurobiol Aging 2011; 32 (Suppl 1): S20-36.
21. Rosen C, Hansson O, Blennow K, et al. Fluid biomarkers in Alzheimer's disease-current concepts. Mol Neurodegener 2013; 8: 20.
22. McIntosh AM,. Toward a systems biology of mood disorder. Biol Psychiatry 2013; 73 (2): 107-108.
23. Machado-Vieira R, Manji HK, Zarate CA,. The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist 2009; 15 (5): 525-539.
24. Iris F,. Psychiatric systems medicine: closer at hand than anticipated but not with the expected portrait. Pharmacopsychiatry 2012; 45 (Suppl 1): S12-21.
25. Kitano H,. Systems biology: a brief overview. Science 2002; 295 (5560): 1662-1664.
26. Hoffman RE, Grasemann U, Gueorguieva R, et al. Using computational patients to evaluate illness mechanisms in schizophrenia. Biol Psychiatry 2011; 69 (10): 997-1005.
27. Zarate CA, Jr., Mathews DC, Furey ML,. Human biomarkers of rapid antidepressant effects. Biol Psychiatry 2013; 73 (12): 1142-1155.
28. Phelps LE, Brutsche N, Moral JR, et al. Family history of alcohol dependence and initial antidepressant response to an N-methyl- d -aspartate antagonist. Biol Psychiatry 2009; 65 (2): 181-184.
29. Luckenbaugh DA, Ibrahim L, Brutsche N, et al. Family history of alcohol dependence and antidepressant response to an N-methyl- d -aspartate antagonist in bipolar depression. Bipolar Disord 2012; 14 (8): 880-887.
30. Laifenfeld D, Drubin DA, Catlett NL, et al. Early patient stratification and predictive biomarkers in drug discovery and development: a case study of ulcerative colitis anti-TNF therapy. Adv Exp Med Biol 2012; 736: 645-653.
31. Mass RD, Press MF, Anderson S, et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6 (3): 240-246.
32. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359 (17): 1757-1765.
33. Han NY, Kim EH, Choi J, et al. Quantitative proteomic approaches in biomarker discovery of inflammatory bowel disease. J Dig Dis 2012; 13 (10): 497-503.
34. Lewis JD,. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140 (6): 1817-1826, e2.
35. Arias AJ, Sewell RA,. Pharmacogenetically driven treatments for alcoholism: are we there yet? CNS Drugs 2012; 26 (6): 461-476.
36. Falcone M, Smith RM, Chenoweth MJ, et al. Neuroimaging in Psychiatric Pharmacogenetics Research: The Promise and Pitfalls. Neuropsychopharmacology 2013; 38 (12): 2327-2337.
37. Papakostas GI, Shelton RC, Kinrys G, et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry 2013; 18 (3): 332-339.
38. Ruhe HG, Mason NS, Schene AH,. Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 2007; 12 (4): 331-359.
39. Anticevic A, Gancsos M, Murray JD, et al. NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci USA 2012; 109 (41): 16720-16725.
40. McNair DM, Frankenthaler LM, Czerlinsky T, et al. Simulated public speaking as a model of clinical anxiety. Psychopharmacology (Berl) 1982; 77 (1): 7-10.
41. Grillon C, Heller R, Hirschhorn E, et al. Acute hydrocortisone treatment increases anxiety but not fear in healthy volunteers: a fear-potentiated startle study. Biol Psychiatry 2011; 69 (6): 549-555.
42. Jick H, Kaye JA, Jick SS,. Antidepressants and the risk of suicidal behaviors. JAMA 2004; 292 (3): 338-343.
43. Simon GE, Savarino J, Operskalski B, et al. Suicide risk during antidepressant treatment. Am J Psychiatry 2006; 163 (1): 41-47.
44. Simon GE, Savarino J,. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 2007; 164 (7): 1029-1034.
45. Tepper SJ, Donnan GA, Dowson AJ, et al. A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin 1999; 15 (4): 254-271.
46. Edmeads J,. Defining response in migraine: which endpoints are important? Eur Neurol 2005; 53 (Suppl 1): 22-28.
47. Zarate CA, Jr., Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl- d -aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63 (8): 856-864.
48. Furey ML, Drevets WC,. Antidepressant efficacy of the antimuscarinic drug scopolamine: a randomized, placebo-controlled clinical trial. Arch Gen Psychiatry 2006; 63 (10): 1121-1129.
49. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329 (5994): 959-964.
50. Voleti B, Navarria A, Liu RJ, et al. Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry 2013; 74 (10): 742-749.
51. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 2010; 329 (5994): 959-964.
52. Denk MC, Rewerts C, Holsboer F, et al. Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. Am J Psychiatry 2011; 168 (7): 751-752.
53. Tanaka C, O'Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008; 26 (10): 1596-1602.
54. Salvadore G, Cornwell BR, Colon-Rosario V, et al. Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry 2009; 65 (4): 289-295.
55. Mayberg HS, Brannan SK, Mahurin RK, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport 1997; 8 (4): 1057-1061.
56. Furey ML, Drevets WC, Hoffman EM, et al. Potential of pretreatment neural activity in the visual cortex during emotional processing to predict treatment response to scopolamine in major depressive disorder. JAMA Psychiatry 2013; 70 (3): 280-290.
57. Poste G,. Bring on the biomarkers. Nature 2011; 469 (7329): 156-157.
58. Poline JB, Breeze JL, Ghosh S, et al. Data sharing in neuroimaging research. Front Neuroinform 2012; 6: 9.